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Background
Recombinant alphavirus replicon particles (VRP), carry-
ing self-amplifying RNA, protects rhesus macaques
against SHIVSF162P4 challenge when used in prime-
boost regimen.
Methods
Novartis has developed a synthetic self-amplifying
mRNA (SAM™) vaccine platform that avoids limitations
of cell culture production and employs synthetic non-
viral vaccine delivery systems.
Results
We evaluated systemic and mucosal immune responses in
mice and rabbits using the SAM™ platform expressing
HIV-1 gp140 (HIV-SAM™ vaccine) prime, protein/MF59
vaccine boost regimen for both HIV-1 Clade B and C Env
antigens. In mice, the primed Env-specific IgG response to
1 µg of the HIV-SAM™ vaccine was comparable to a 10
µg dose of an identically formulated DNA vaccine, 10(7)
IU of VRP, and 10 µg protein/MF59 vaccines. The HIV-
SAM™ vaccine primed response could be boosted
robustly by a protein/MF59 vaccine and resulted in a
balanced IgG1, IgG2a subclass response, similar to that
seen with the VRP vaccine, but unlike the dominant IgG1
response to protein/MF59 only vaccinations. Both Env-
specific CD4+ and CD8+ T-cell responses were detectable
after two HIV-SAM™ vaccinations. A TH1 type (IFNg+,
IL-5-) profile was demonstrable for the HIV-SAM™ vac-
cine primed, protein boosted CD4+ T-cell response, simi-
lar to that seen with the DNA or VRP primed protein
boosted responses, in contrast to a TH2 type (IFNglow,
IL-5+) response seen with protein/MF59 vaccination. In
rabbits, priming with the 25 or 50 µg of the formulated
HIV-SAM™ vaccine induced robust and avid Env-binding
IgG and HIV neutralizing antibodies that were superior to
500 µg of an unformulated DNA vaccine and comparable
to VRP and protein/MF59 vaccines. In addition, protein/
MF59 boostable Env-specific vaginal wash Ig was consis-
tently demonstrable in both mice and rabbits immunized
with the HIV-SAM™.
Conclusion
Together, these results suggest that HIV-SAM™ vaccine is
potent and versatile and offers potential as a novel immune
priming strategy. NIAID-NIH Grant 5P01AI066287.
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